EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)VergleichsstudieRandomisierte kontrollierte Studie

Improved Outcomes with Enzalutamide in Biochemically Recurrent Prostate Cancer

Stephen J Freedland, Murilo de Almeida Luz, Ugo De Giorgi iD, Martin Gleave, Geoffrey T Gotto, Christopher M Pieczonka, Gabriel P Haas, Choung-Soo Kim, Miguel Ramirez-Backhaus, Antti Rannikko, Jamal Tarazi, Swetha Sridharan und 9 weitere

New England Journal of Medicine · 19.10.2023 · 389 (16) · 1453-1465

DOI: 10.1056/nejmoa2303974 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift New England Journal of Medicine, erschienen am 19.10.2023. Verfasst von Stephen J Freedland und 20 weiteren Autor:innen. Beteiligte Einrichtung: From the Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles (S.J.F.); the Durham Veterans Affairs Health Care Sys…. Hauptthemen laut MEDLINE: Androgen Antagonists, Leuprolide, Prostatic Neoplasms, Antineoplastic Agents. Die Arbeit wurde bisher 328-mal zitiert (Crossref) und nennt 40 Literaturangaben. Gefördert von: Pfizer, Astellas Pharma US.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Androgen AntagonistsLeuprolideProstatic NeoplasmsAntineoplastic AgentsNeoplasm Recurrence, LocalHumansMaleNitrilesQuality of LifeDrug Therapy, CombinationBenzamidesPhenylthiohydantoin

Substanzen

Androgen AntagonistsLeuprolideNitrilesAntineoplastic AgentsenzalutamideBenzamidesPhenylthiohydantoin

Autor:innen und Institutionen

  • From the Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles (S.J.F.); the Durham Veterans Affairs Health Care System, Durham, NC (S.J.F.); the Division of Urologic Oncology, Erasto Ga…

ORCID-Profile: Ugo De Giorgi, Henry H Woo

Förderung

  • Pfizer
  • Astellas Pharma US

Zitieren

APA

Freedland, S. J., de Almeida Luz, M., De Giorgi, U., Gleave, M., Gotto, G. T., Pieczonka, C. M., Haas, G. P., Kim, C. S., Ramirez-Backhaus, M., Rannikko, A., Tarazi, J., Sridharan, S., Sugg, J., Tang, Y., Tutrone, R. F., Venugopal, B., Villers, A., Woo, H. H., Zohren, F., …, & EMBARK Study (2023). Improved Outcomes with Enzalutamide in Biochemically Recurrent Prostate Cancer. New England Journal of Medicine, 389(16), 1453-1465. https://doi.org/10.1056/nejmoa2303974

Vancouver

Freedland SJ, de Almeida Luz M, De Giorgi U, Gleave M, Gotto GT, Pieczonka CM, et al. Improved Outcomes with Enzalutamide in Biochemically Recurrent Prostate Cancer. New England Journal of Medicine. 2023;389(16):1453-1465. doi:10.1056/nejmoa2303974

BibTeX
@article{Freedland2023,
  author = {Freedland, Stephen J and de Almeida Luz, Murilo and De Giorgi, Ugo and Gleave, Martin and Gotto, Geoffrey T and Pieczonka, Christopher M and Haas, Gabriel P and Kim, Choung-Soo and Ramirez-Backhaus, Miguel and Rannikko, Antti and Tarazi, Jamal and Sridharan, Swetha and Sugg, Jennifer and Tang, Yiyun and Tutrone, Ronald F and Venugopal, Balaji and Villers, Arnauld and Woo, Henry H and Zohren, Fabian and Shore, Neal D and EMBARK Study, EMBARK Study},
  title = {Improved Outcomes with Enzalutamide in Biochemically Recurrent Prostate Cancer},
  journal = {New England Journal of Medicine},
  year = {2023},
  volume = {389},
  number = {16},
  pages = {1453--1465},
  doi = {10.1056/nejmoa2303974}
}
Kostenlos starten →